Delcath Systems Inc
NASDAQ:DCTH

Watchlist Manager
Delcath Systems Inc Logo
Delcath Systems Inc
NASDAQ:DCTH
Watchlist
Price: 11.23 USD -1.84%
Market Cap: 359m USD
Have any thoughts about
Delcath Systems Inc?
Write Note

Operating Margin
Delcath Systems Inc

-118.2%
Current
-980%
Average
4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-118.2%
=
Operating Profit
-26.8m
/
Revenue
22.6m

Operating Margin Across Competitors

Country US
Market Cap 365.7m USD
Operating Margin
-118%
Country US
Market Cap 198.3B USD
Operating Margin
17%
Country US
Market Cap 189.1B USD
Operating Margin
26%
Country US
Market Cap 140.4B USD
Operating Margin
22%
Country US
Market Cap 132.3B USD
Operating Margin
18%
Country IE
Market Cap 104.2B USD
Operating Margin
19%
Country US
Market Cap 65.2B USD
Operating Margin
14%
Country DE
Market Cap 58.1B EUR
Operating Margin
12%
Country US
Market Cap 44.1B USD
Operating Margin
28%
Country CN
Market Cap 309.1B CNY
Operating Margin
36%
Country US
Market Cap 36.2B USD
Operating Margin
13%
No Stocks Found

Delcath Systems Inc
Glance View

Market Cap
359m USD
Industry
Health Care

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

DCTH Intrinsic Value
12.95 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-118.2%
=
Operating Profit
-26.8m
/
Revenue
22.6m
What is the Operating Margin of Delcath Systems Inc?

Based on Delcath Systems Inc's most recent financial statements, the company has Operating Margin of -118.2%.